sodium chloride 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4198	7647-14-5

Description:

Molecule	Description
Synonyms: sodium chloride	A ubiquitous sodium salt that is commonly used to season food. Molecular weight: 58.44 Formula: ClNa CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

sodium chloride

A ubiquitous sodium salt that is commonly used to season food.

Molecular weight: 58.44
Formula: ClNa
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
1	g	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Dec. 16, 1965	FDA	HOSPIRA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myelosuppression	2609.76	10.41	1117	109828	22586	63355491
Agranulocytosis	923.40	10.41	565	110380	24569	63353508
Infective pulmonary exacerbation of cystic fibrosis	799.87	10.41	363	110582	8454	63369623
White blood cell count decreased	680.04	10.41	1014	109931	138090	63239987
Bone marrow failure	526.40	10.41	425	110520	28865	63349212
Hereditary angioedema	475.10	10.41	242	110703	7320	63370757
Drug intolerance	355.33	10.41	57	110888	308604	63069473
Neutrophil count decreased	332.45	10.41	450	110495	55956	63322121
Hyperchloraemia	324.51	10.41	98	110847	665	63377412
Contraindicated product administered	324.05	10.41	13	110932	217635	63160442

Showing 1 to 10 of 438 entries

Previous1 2 3 4 5…44Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myelosuppression	770.87	10.51	494	75067	18771	34862599
Infective pulmonary exacerbation of cystic fibrosis	696.52	10.51	325	75236	6476	34874894
Hyperchloraemia	412.25	10.51	113	75448	393	34880977
Peritonitis bacterial	354.23	10.51	199	75362	5911	34875459
Peritoneal dialysis complication	240.22	10.51	102	75459	1607	34879763
Cystic fibrosis	194.11	10.51	87	75474	1571	34879799
Drug ineffective	186.44	10.51	449	75112	456302	34425068
Fungal peritonitis	170.21	10.51	64	75497	719	34880651
Peritonitis	168.31	10.51	192	75369	16173	34865197
Completed suicide	163.15	10.51	13	75548	98155	34783215

Showing 1 to 10 of 296 entries

Previous1 2 3 4 5…30Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myelosuppression	3305.35	9.86	1585	149597	38711	79554495
Infective pulmonary exacerbation of cystic fibrosis	1264.95	9.86	574	150608	12277	79580929
White blood cell count decreased	849.21	9.86	1382	149800	186906	79406300
Agranulocytosis	675.83	9.86	610	150572	44420	79548786
Bone marrow failure	608.25	9.86	609	150573	50498	79542708
Peritonitis bacterial	440.01	9.86	256	150926	9311	79583895
Neutrophil count decreased	432.92	9.86	697	150485	93262	79499944
Completed suicide	374.39	9.86	23	151159	245744	79347462
Cystic fibrosis	358.78	9.86	166	151016	3714	79589492
Chills	344.99	9.86	865	150317	159369	79433837

Showing 1 to 10 of 567 entries

Previous1 2 3 4 5…57Next

FDA Adverse Event Reporting System (Pediatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neurotoxicity	32.17	25.92	8	294	8	89482
Bone marrow failure	32.17	25.92	8	294	8	89482
Gasping syndrome	32.17	25.92	8	294	8	89482
Toxicity to various agents	31.62	25.92	15	287	199	89291
Circulatory collapse	30.07	25.92	10	292	46	89444

Showing 1 to 5 of 5 entries

Previous1Next

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	A12CA01	ALIMENTARY TRACT AND METABOLISM MINERAL SUPPLEMENTS OTHER MINERAL SUPPLEMENTS Sodium
ATC	B05CB01	BLOOD AND BLOOD FORMING ORGANS BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS IRRIGATING SOLUTIONS Salt solutions
ATC	B05XA03	BLOOD AND BLOOD FORMING ORGANS BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS I.V. SOLUTION ADDITIVES Electrolyte solutions
ATC	S01XA03	SENSORY ORGANS OPHTHALMOLOGICALS OTHER OPHTHALMOLOGICALS Other ophthalmologicals
CHEBI has role	CHEBI:79314	flame retardants
CHEBI has role	CHEBI:149552	emetics

Showing 1 to 6 of 6 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

Show entries

Search:

Species	Use	Relation
Multiple Species	Restore circulatory volume and maintain blood pressure in animals being treated for shock	Indication
Multiple Species	Early treatment of scouring	Indication
Multiple Species	Treatment following intravenous fluid therapy	Indication
Multiple Species	Early treatment of scouring	Indication

Showing 1 to 4 of 4 entries

Previous1Next

🐶 Veterinary products

Product	Applicant	Ingredients
Intragel	Zoetis Inc.	2
Re-Sorb, Vytrate	Zoetis Inc.	6

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.21GM/100ML;2.8GM/100ML;9.07GM/100ML	NORMOCARB HF 25	DIALYSIS SUPS	N021910	July 26, 2006	RX	SOLUTION	INJECTION	7300674	March 4, 2023	USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY
7.54GM;140GM;2.2GM;48.11GM;5.2GM;9GM	PLENVU	SALIX	N209381	May 4, 2018	RX	FOR SOLUTION	ORAL	10792306	March 9, 2032	FOR CLEANSING OF THE COLON IN PREPARATION FOR COLONOSCOPY IN ADULTS
7.54GM;140GM;2.2GM;48.11GM;5.2GM;9GM	PLENVU	SALIX	N209381	May 4, 2018	RX	FOR SOLUTION	ORAL	11529368	March 9, 2032	FOR CLEANSING OF THE COLON IN PREPARATION FOR COLONOSCOPY IN ADULTS
7.54GM;140GM;2.2GM;48.11GM;5.2GM;9GM	PLENVU	SALIX	N209381	May 4, 2018	RX	FOR SOLUTION	ORAL	9592252	Aug. 11, 2032	FOR CLEANSING OF THE COLON IN PREPARATION FOR COLONOSCOPY IN ADULTS
7.54GM;140GM;2.2GM;48.11GM;5.2GM;9GM	PLENVU	SALIX	N209381	May 4, 2018	RX	FOR SOLUTION	ORAL	10918723	Sept. 10, 2033	FOR CLEANSING OF THE COLON IN PREPARATION FOR COLONOSCOPY IN ADULTS
7.54GM;140GM;2.2GM;48.11GM;5.2GM;9GM	PLENVU	SALIX	N209381	May 4, 2018	RX	FOR SOLUTION	ORAL	9326969	Sept. 10, 2033	FOR CLEANSING OF THE COLON IN PREPARATION FOR COLONOSCOPY IN ADULTS

Showing 1 to 6 of 6 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
0.9GM/BOT;178.7GM/BOT;1.12GM/BOT;0.5GM/BOT;7.3GM/BOT	SUFLAVE	BRAINTREE LABS	N215344	June 15, 2023	RX	FOR SOLUTION	ORAL	June 15, 2026	NEW PRODUCT
234MG/ML	SODIUM CHLORIDE 23.4%	FRESENIUS KABI USA	A217796	July 11, 2023	RX	INJECTABLE	INJECTION	Jan. 23, 2024	COMPETITIVE GENERIC THERAPY

Showing 1 to 2 of 2 entries

Previous1Next

Bioactivity Summary:

None

External reference:

Show entries

Search:

ID	Source
000759	NDDF
002238	NDDF
387390002	SNOMEDCT_US
4017444	VUID
4017444	VANDF
4155	INN_ID
451W47IQ8X	UNII
5234	PUBCHEM_CID
5476	MMSL
6383	MMSL

Showing 1 to 10 of 21 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Balanced Salt	HUMAN PRESCRIPTION DRUG LABEL	6	0264-1945	SOLUTION	6.40 mg	IRRIGATION	ANDA	11 sections
BSS	HUMAN PRESCRIPTION DRUG LABEL	6	0065-0795	SOLUTION	6.40 mg	OPHTHALMIC	NDA	9 sections
BSS	HUMAN PRESCRIPTION DRUG LABEL	6	0065-0795	SOLUTION	6.40 mg	OPHTHALMIC	NDA	9 sections
BSS	HUMAN PRESCRIPTION DRUG LABEL	6	0065-0795	SOLUTION	6.40 mg	OPHTHALMIC	NDA	9 sections
BSS	HUMAN PRESCRIPTION DRUG LABEL	6	0065-0795	SOLUTION	6.40 mg	OPHTHALMIC	NDA	9 sections
BSS	HUMAN PRESCRIPTION DRUG LABEL	6	0065-1795	SOLUTION	6.40 mg	OPHTHALMIC	NDA	9 sections
BSS	HUMAN PRESCRIPTION DRUG LABEL	6	0065-1795	SOLUTION	6.40 mg	OPHTHALMIC	NDA	9 sections
HESPAN	HUMAN PRESCRIPTION DRUG LABEL	2	0264-1965	INJECTION, SOLUTION	0.90 g	INTRAVENOUS	NDA	22 sections
HESPAN	HUMAN PRESCRIPTION DRUG LABEL	2	0264-1965	INJECTION, SOLUTION	0.90 g	INTRAVENOUS	NDA	22 sections
HyperlyteCR	HUMAN PRESCRIPTION DRUG LABEL	5	0264-1943	INJECTION, SOLUTION, CONCENTRATE	1.17 g	INTRAVENOUS	UNAPPROVED DRUG OTHER	18 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next